About Early growth response protein 1
Early growth response protein 1 (EGR1) is a protein
from Homo sapiens identified by UniProt accession
P18146, 543 residues long.
MolForge cross-references it against 0 known binders and
777 disease associations.
Target properties
| Protein name | Early growth response protein 1 |
| UniProt accession | P18146 |
| Gene | EGR1 |
| Organism | Homo sapiens |
| Length | 543 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (777)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.37
- sex hormone-binding globulin measurement · score 0.32
- testosterone measurement · score 0.28
- hepatocellular carcinoma · score 0.12
- squamous cell carcinoma · score 0.12
- neoplasm · score 0.12
- pain · score 0.11
- infection · score 0.10
- infect · score 0.10
- breast cancer · score 0.10
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P18146-F1 | alphafold | PREDICTED | 49.64 | — |
Amino-acid sequence (543 residues)
MAAAKAEMQL MSPLQISDPF GSFPHSPTMD NYPKLEEMML LSNGAPQFLG AAGAPEGSGS NSSSSSSGGG GGGGGGSNSS SSSSTFNPQA DTGEQPYEHL TAESFPDISL NNEKVLVETS YPSQTTRLPP ITYTGRFSLE PAPNSGNTLW PEPLFSLVSG LVSMTNPPAS SSSAPSPAAS SASASQSPPL SCAVPSNDSS PIYSAAPTFP TPNTDIFPEP QSQAFPGSAG TALQYPPPAY PAAKGGFQVP MIPDYLFPQQ QGDLGLGTPD QKPFQGLESR TQQPSLTPLS TIKAFATQSG SQDLKALNTS YQSQLIKPSR MRKYPNRPSK TPPHERPYAC PVESCDRRFS RSDELTRHIR IHTGQKPFQC RICMRNFSRS DHLTTHIRTH TGEKPFACDI CGRKFARSDE RKRHTKIHLR QKDKKADKSV VASSATSSLS SYPSPVATSY PSPVTTSYPS PATTSYPSPV PTSFSSPGSS TYPSPVHSGF PSPSVATTYS SVPPAFPAQV SSFPSSAVTN SFSASTGLSD MTATFSPRTI EIC
Explore Early growth response protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets